Abstract
Introduction HIV elimination requires innovative approaches to ensure testing and immediate treatment provision. We investigated the effectiveness of conditional financial incentives on increasing linkage to HIV care in a 2×2 factorial cluster randomized controlled trial-Home-Based Intervention to Test and Start (HITS) - in rural South Africa.
Methods Of 45 communities in uMkhanyakude, KwaZulu-Natal, 16 communities were randomly assigned to the arms to receive financial incentives for home-based HIV counseling and testing (HBHCT) and linkage to care within 6 weeks (R50 [US$3] food voucher each) and 29 communities to the arms without financial incentives. We examined linkage to care (i.e., initiation or resumption of antiretroviral therapy after >3 months of care interruption) at local clinics within 6 weeks of a home visit, the eligibility period to receive the second financial incentive. Linkage to care was ascertained from individual clinical records. Intention-to-treat analysis (ITT) was performed using modified Poisson regression with adjustment for receiving another intervention (i.e., male-targeted HIV-specific decision support app) and clustering of standard errors at the community level.
Results Among 13,894 eligible men (i.e., ≥15 years and resident in the 45 communities), 20.7% received HBHCT, which resulted in 122 HIV-positive tests. Of these, 27 linked to care within 6 weeks of HBHCT. Additionally, of eligible men who did not receive HBHCT, 66 linked to care. In the ITT analysis, the proportion of linkage to care among men did not differ in the arms which received financial incentives and those without financial incentives (adjusted Risk Ratio [aRR]=0.78, 95% CI: 0.51-1.21). Among 19,884 eligible women, 29.1% received HBHCT, which resulted in 375 HIV-positive tests. Of these, 75 linked to care. Among eligible women who did not receive HBHCT, 121 linked to care within 6 weeks. Women in the financial incentive arms had a significantly higher probability of linkage to care, compared to those in the arms without financial incentives (aRR=1.50; 95% CI: 1.03-2.21).
Conclusion While a small once-off financial incentive did not increase linkage to care among men during the eligibility period of 6 weeks, it significantly improved linkage to care among women over the same period.
Clinical Trial Number: ClinicalTrials.gov # NCT03757104
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
ClinicalTrials.gov # NCT03757104
Funding Statement
The research is funded by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) under Award Number R01AI124389 (PIs: FT and TB). EPIC-HIV development was supported by the Engineering and Physical Sciences Research Council (EPSRC) Interdisciplinary Research Collaboration (IRC) Early-warning Sensing Systems for Infectious Diseases (i-sense) EP/K031953/1 and MRC MR/P024378/1. FT and TB are supported by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (Award # R01-HD084233), and FT is additionally supported by the National Institute of Mental Health (NIMH) (Award # R01MH131480). NM is a recipient of an NIHR Research Professorship award (RP-2017-08-ST2-008). The Africa Health Research Institute's HDSS is funded by the Wellcome Trust (201433/A/16/A), and the South Africa Population Research Infrastructure Network (funded by the South African Department of Science and Technology and hosted by the South African Medical Research Council). The content is solely the responsibility of the authors and does not necessarily represent the official views of the funding bodies.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study protocols for the AHRI's population-based HIV testing platform and HITS intervention were approved by the Biomedical Research Ethics Committee of the University of KwaZulu-Natal (BE290/16 and BFC398/16).36 Permission for the trial was obtained from the KwaZulu-Natal Department of Health, South Africa. Participation in the HIV surveillance and HITS trial is completely voluntary. Individuals may choose not to answer and/or participate in any component of the HIV surveillance and to withdraw at any time. Written informed consent was sought from individuals aged ≥ 18 years, and parental or guardian consent with child assent for individuals of 15-17 years old were obtained.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The data underlying the results presented in the study are available from the AHRI Data Repository (https://data.ahri.org) for researchers who meet the criteria for access to confidential data and sign on the agreement according to the AHRI's protocol for data sharing. The authors confirm they did not have any special access or privileges that others would not have.
